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Abstract
The role of dietary calcium in cardiovascular disease prevention is unclear. We aimed to determine the association between 
calcium intake and incident cardiovascular disease and mortality. Data were extracted from the European Prospective Inves-
tigation of Cancer, Norfolk (EPIC-Norfolk). Multivariable Cox regressions analysed associations between calcium intake 
(dietary and supplemental) and cardiovascular disease (myocardial infarction, stroke, heart failure, aortic stenosis, peripheral 
vascular disease) and mortality (cardiovascular and all-cause). The results of this study were pooled with those from published 
prospective cohort studies in a meta-analsyis, stratifying by average calcium intake using a 700 mg/day threshold. A total 
of 17,968 participants aged 40–79 years were followed up for a median of 20.36 years (20.32–20.38). Compared to the first 
quintile of calcium intake (< 770 mg/day), intakes between 771 and 926 mg/day (second quintile) and 1074–1254 mg/day 
(fourth quintile) were associated with reduced all-cause mortality (HR 0.91 (0.83–0.99) and 0.85 (0.77–0.93), respectively) 
and cardiovascular mortality [HR 0.95 (0.87–1.04) and 0.93 (0.83-1.04)]. Compared to the first quintile of calcium intake, 
second, third, fourth, but not fifth quintiles were associated with fewer incident strokes: respective HR 0.84 (0.72–0.97), 
0.83 (0.71–0.97), 0.78 (0.66–0.92) and 0.95 (0.78–1.15). The meta-analysis results suggest that high levels of calcium 
intake were associated with decreased all-cause mortality, but not cardiovascular mortality, regardless of average calcium 
intake. Calcium supplementation was associated with cardiovascular and all-cause mortality amongst women, but not men. 
Moderate dietary calcium intake may protect against cardiovascular and all-cause mortality and incident stroke. Calcium 
supplementation may reduce mortality in women.
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Introduction
The role of dietary calcium intake and calcium supplemen-
tation in cardiovascular disease (CVD) prevention remains 
controversial [1]. Whilst some studies advocate that higher 
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calcium intake may be associated with higher mortality [2, 
3], others suggest the contrary [4, 5]. Furthermore, conflict-
ing evidence exists regarding calcium supplementation and 
its effects on important determinants of adverse cardiovas-
cular outcomes. Whilst there is evidence to suggest that 
increased calcium intake is associated with improved lipid 
profiles [6] and reduced blood pressure [7], increased serum 
calcium levels have also been associated with an increase 
in arterial calcification [8]. Furthermore, several Mende-
lian randomisation studies have underlined the relationship 
between increases in serum calcium levels and increased 
incidence of coronary artery disease [9] and myocardial 
infarction [9, 10], but not ischaemic stroke [11]. Despite 
several previous systematic reviews and meta-analyses hav-
ing analysed this relationship, these have yielded conflict-
ing results in terms of both incident cardiovascular disease 
(CVD) and mortality [12–16].
To our knowledge, no prospective cohort studies have 
examined the relationship between calcium intake or sup-
plementation and incident cardiovascular disease or mortal-
ity in the British population over very long-term follow-up.
In view of this literature gap, we utilised data from Euro-
pean Prospective Investigation into Cancer (EPIC)-Norfolk 
prospective population-based study to evaluate the asso-
ciation between calcium intake (dietary intake and supple-
ment use) and mortality and incident CVD over very long 
follow-up in excess of 20 years and incorporate these results 




Participants were selected from the European Prospective 
Investigation into Cancer, Norfolk (EPIC-Norfolk) pro-
spective cohort study. Study recruitment methods have 
been described in detail previously [17]. In brief, men and 
women aged 40–79 (at study baseline) from 35 participat-
ing General Practices in Norfolk, England were invited to 
participate. This study was approved by the Norwich Local 
Research Ethics Committee. All participants provided 
signed informed consent.
Dietary data collection
Dietary calcium and vitamin D intake were estimated from 
a food frequency questionnaire (FFQ) which contained a 
list of 130 foods and was designed to measure the usual 
food intake of participants during the previous year. Addi-
tional questions gathered specific information on the type 
and amount of cereal, fat and milk consumed and the use 
of any vitamin or mineral supplements (including calcium 
supplements).
Non‑dietary data collection
Non-dietary data were collected from a health and lifestyle 
questionnaire (HLQ) and by the means of a health check. 
Smoking history was obtained using the questions “Have 
you ever smoked as much as one cigarette a day for as long 
as a year?” and “Do you smoke cigarettes now?”; education 
level was recorded as no qualification, O-level, A-level or 
degree or higher qualification; and social class was classified 
according to the Registrar General’s occupation-based clas-
sification scheme [18, 19]. Medical history was determined 
using the question “Has a doctor ever told you that you have 
any of the following?” followed by a list of medical condi-
tions including high blood pressure, cancer, heart attack, 
stroke and diabetes. In addition, a four-level physical activity 
index was derived from the validated EPIC short physical 
activity questionnaire designed to assess combined work and 
leisure activity [20].
At the health check, trained nurses measured height, 
weight, blood pressure and collected blood samples. Weight 
was measured to the nearest 0.2 kg using digital scales 
(Salter, UK) with participants wearing light clothing with-
out shoes, and height was measured to the nearest 0.1 cm 
using a stadiometer with shoes removed. Body mass index 
(BMI, kg/m2) was calculated as weight (kg) divided by the 
square of the height  (m2). Blood pressure (BP) was measured 
with an Accutorr sphygmomanometer (Datascope, UK) after 
the participant had been seated for 3 min, and the mean of 
two BP measurements was used for analysis. Serum total 
cholesterol was measured from non-fasting venous blood 
samples with an RA 1000 (Bayer Diagnostics, Basingstoke, 
UK). A total of 25,639 participants completed all baseline 
components and attended the health check.
Outcomes
International Classification of Disease 10 (ICD-10) codes 
were used to define the outcomes for the study: all-cause 
mortality, cardiovascular mortality, incident all cardiovas-
cular disease, incident aortic stenosis, incident heart failure, 
incident myocardial infarction, incident peripheral vascular 
disease and incident stroke. Cardiovascular events evalu-
ated were myocardial infarction (I21–22), stroke (I60–I69), 
heart failure (I50), aortic stenosis (I35), peripheral vascu-
lar disease (I70–79). The composite cardiovascular disease 
outcome was defined as I10–79. In addition, data from the 
Office of National Statistics were used to ascertain all-cause 
mortality (up to March 2016). Cardiovascular mortality was 
defined as death with a cause of death listed as I10–79. Fur-
thermore, all participants were linked to National Health 
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Service hospital information system and ENCORE (East 
Norfolk Commission Record) to allow notification of any 
hospital admission. While validation studies have not been 
performed for all the diagnoses and outcomes from EPIC-
Norfolk included in this study, previously published valida-
tion studies of random samples from EPIC-Norfolk assess-
ing the diagnoses of stroke [21], heart failure [22] and the 
physical activity questionnaire [20] have shown that these 
parameters were ascertained with high accuracy. These 
studies overall suggest the high validity of the diagnoses 
ascertained in the EPIC-Norfolk cohort. Furthermore, the 
United Kingdom National Health Service (NHS) captures 
almost all events as everyone in the UK is registered with 
a General Practitioner and has an associated NHS number. 
Therefore, data capture using NHS record linkage system is 
extremely robust.
Statistical analysis
Data were analysed using Stata 15.1 SE (StataCorp 2017, 
Stata Statistical Software: Release 15, College Station, TX: 
StataCorp LLC). Participants with missing or invalid covari-
ate data and those with prevalent cancer or cardiovascular 
disease (stroke, myocardial infarction) were excluded. Par-
ticipants were categorised by quintiles of dietary calcium 
intake in order to allow comparison with the results yielded 
by previous nutritional epidemiology studies as well as to 
allow modelling of non-linear relationships between calcium 
intake and outcomes whilst providing clinically meaningful 
thresholds of recommended intake. Participants were also 
dichotomised by usage of calcium supplements (use vs. 
no use). Baseline characteristics were compared between 
groups using the χ2 test and one-way ANOVA for categorical 
and continuous variables, respectively.
Primary analyses
Cox proportional hazard models were used to calculate the 
risk of mortality (all-cause and cardiovascular) associated 
with calcium exposure. Models were constructed quantifying 
the association between: (1) calcium exposure (as quintiles 
of calcium intake) and pre-specified outcomes and (2) use 
of calcium supplements and pre-specified outcomes. Mul-
tivariable adjustments were chosen based on clinical judge-
ment and previous literature [2–5, 23–25]. All analyses were 
adjusted for demographic data (age, sex), biological factors 
(BMI, systolic blood pressure, low-density lipoprotein, high-
density lipoprotein and total cholesterol levels), social class, 
education level, lifestyle factors (physical activity, alcohol 
intake, smoking status—current/former/never smoker), pre-
existing comorbidities (hypertension, diabetes), medication 
and supplement use (aspirin, statins, ACE inhibitors, beta-
blockers, angiotensin receptor blockers, vitamin supplement 
use, calcium supplement use),dietary intake (total energy 
intake, fruit and vegetable, vitamin D) and current/former 
usage of hormone replacement therapy (HRT).
Secondary analyses
Secondary analyses were also performed in order to evalu-
ate the sex-stratified relationship between quintiles of cal-
cium intake and the pre-specified outcomes. Furthermore, 
the relationship between quintiles of calcium intake and the 
pre-specified outcomes was also evaluated among (1) par-
ticipants without prevalent hypertension or diabetes mellitus 
at baseline and (2) female participants ever having used HRT 
at baseline. Finally, in order to evaluate the non-linear asso-
ciations between calcium intake and the pre-specified out-
comes, restricted cubic splines (RCSs) were used to model 
the hazard ratio associated with calcium intake as a continu-
ous variable for each outcome as a flexible non-linear func-
tion, where appropriate. The Akaike Information Criterion 
was calculated for the linear model and for RCS models with 
varying degrees of freedom (df = 2 to df = 7). The model 
with the lowest AIC was chosen for each outcome. Where 
an RCS model had a lower AIC than the linear model, the 
likelihood-ratio test was used to confirm that this RCS model 
provides a better fit for the data than the linear model. Sup-
plementary Table 1 details the best fitting models for each 
regression. The mean calcium intake (1018.83 mg/day) was 
used as reference for all analyses.
Meta‑analysis
A systematic search on Medline was conducted up to Sep-
tember 2020 for prospective cohort studies that evaluated 
the association between calcium dietary intake or sup-
plementation and cardiovascular mortality or all cause-
mortality. The following search terms were utilised: cal-
cium [ti] AND ((“cardiovascular system”[MeSH Terms] 
OR (“cardiovascular”[All Fields] AND “system”[All 
Fields]) OR “cardiovascular system”[All Fields] OR 
“cardiovascular”[All Fields]) OR (“stroke”[MeSH Terms] 
OR “stroke”[All Fields])) AND (diet * OR supplementv* OR 
intake). In addition to the studies thus identified, we also 
included all studies that had been included in previously 
published systematic reviews and meta-analyses [12–15].
We conducted an updated systematic review and meta-
analysis evaluating the association between high dietary cal-
cium intake or calcium supplementation and mortality (car-
diovascular and all-cause). We included in the meta-analyses 
all eligible studies identified by the literature search, those 
identified by the reference analysis of previously published 
meta-analyses, as well as the current study. Figure 1 details 
the PRISMA flow diagram. We have thus identified 26 
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prospective cohort studies with a total of 1,828,149 partici-
pants [2–5, 23–44]. Details of the studies characteristics and 
results are shown in Supplementary Tables 2 and 3.
The meta-analysis was performed using STATA version 
13.0 (College Station, TX). Pooled relative risk (RR) and 
95% confidence intervals were calculated using Der-Simo-
nian and Laird method using random effects meta-analysis, 
taking into account conceptual heterogeneity. Odds ratios, 
hazard ratios and risk ratios were meta-analysed together 
and the results expressed as risk ratios, as the outcomes of 
interest are rare events. Given that included studies exhibited 
highly heterogenous calcium intake values, stratified meta-
analysis was performed by average calcium intake, using 
700 mg/day as threshold. Stratified meta-analyses were also 
performed by sex.
Fig. 1  PRISMA Flow Diagram




Supplementary Figure 1 details the participant population 
flowchart. A total of 17,968 men and women from the 
EPIC-Norfolk study were included in the analysis after the 
exclusion of participants with missing data on key vari-
ables and those with prevalent cancer or cardiovascular 
disease (myocardial infarction or stroke) at baseline. The 
mean age (SD) was 58.8 (9.2) years and there were 44.1% 
men. Patients were followed up for median (95%CI) of 
7435 (7421–7442) days–20.36 (20.32–20.38) years. Total 
follow-up was 119,909,424 person-years. The character-
istics of included and excluded participants are shown in 
Supplementary Table 4.
Dietary calcium intake, mortality and cardiovascular 
disease
Table 1 displays the characteristics of participants divided 
by quintiles of calcium intake: calcium intake less than 
770 mg/day was considered as the first quintile, whilst 
intakes between 771 and 926 mg/day, 927 and 1073 mg/
day, 1074 and 1254 mg/day and more than 1254 mg/day 
represented the second, third, fourth and fifth quintiles 
respectively. Patients with a higher dietary calcium intake 
were predominantly male, had a lower body mass index 
(BMI), lower cholesterol levels, higher educational level, 
higher physical activity levels, lower levels alcohol con-
sumption and were in greater proportion never smokers. 
Furthermore, participants with higher dietary calcium 
intake had higher total daily energy intake, fruit, vege-
table and Vitamin D intake. Furthermore, they also had 
increased vitamin and calcium supplement use.
Table 2 details the results of the multivariable Cox 
regression models. Compared to the first quintile of cal-
cium intake (< 770 mg/day), the second (771–926 mg/
day) and fourth (1074–1254 mg/day) quintiles of cal-
cium intake were associated with lower all-cause mor-
tality, respective HR (95%CI): 0.91 (0.83–0.99) and 
0.85 (0.77–0.93). There were no associations between 
the third (1074–1254 mg/day) and fifth (≥ 1255 mg/day) 
quintiles of calcium intake and all-cause mortality, respec-
tive HR (95%CI): 0.95 (0.87–1.04) and 0.93 (0.83–1.04). 
Similarly, compared to the first quintile of calcium intake 
(< 770 mg/day), the second (771–926 mg/day) and fourth 
(1074–1254  mg/day) quintiles were associated with 
decreased cardiovascular mortality: HR (95%CI): 0.79 
(0.67–0.93) and 0.80 (0.67–0.95) respectively. There 
were no associations between the third (1074–1254 mg/
day) and fifth (≥ 1255 mg/day) quintiles of calcium intake 
and cardiovascular mortality, respective HR (95%CI): 0.90 
(0.76–1.06) and 0.87 (0.71–1.07). Furthermore, com-
pared to the first quintile of calcium intake (< 770 mg/
day), the second (771–926 mg/day), third (927–1073 mg/
day) and fourth (1074–1254 mg/day) quintiles were asso-
ciated with a decreased rate of incident stroke, respec-
tive HR (95%CI): 0.84 (0.72–0.97), 0.83 (0.71–0.97) 
and 0.78 (0.66–0.92). There was no association between 
the fifth quintile (≥ 1255 mg/day) of calcium intake and 
incident stroke: 0.95 (0.78–1.15). There were no associa-
tions between calcium intake and incident cardiovascular 
disease, incident aortic stenosis, incident cardiac failure, 
incident myocardial infarction or incident peripheral vas-
cular disease.
Supplemental calcium supplement, mortality 
and cardiovascular disease
Calcium supplement use was more common among partici-
pants who were older and female as well as those who had 
lower BMI, higher social status and higher education level 
(Supplementary Table 5). They were also more likely to have 
a higher level of physical activity, consume less alcohol and 
were in greater proportion never smokers. Calcium supple-
ment use was associated with higher dietary calcium intake 
and increased vitamin supplement use. Calcium supplement 
users had a lower incidence of myocardial infarction, and 
peripheral vascular disease compared to those who did not 
use calcium supplements. Upon multivariable analysis, there 
was no significant association between calcium supplement 
use and any outcome (Table 3).
Secondary Analyses
There were several significant sex differences in the asso-
ciation between calcium intake and cardiovascular mortal-
ity and incident stroke (Supplementary Table 6). While 
amongst men, higher daily calcium intake (≥ 771 mg/day) 
was associated with 26–40% lower risk of cardiovascular 
mortality compared to the lowest calcium intake quintile 
(≤ 770 mg/day), there were no statistically significant asso-
ciations between calcium intake and cardiovascular mor-
tality amongst women. Similarly, while amongst men, the 
second (771–926 mg/day), third (927–2073 mg/day), and 
fourth (1074–1254 mg/day) quintiles of daily calcium intake 
were associated with 14–24% decreased risk of incident 
stroke compared to the lowest quintile of calcium intake 
(≤ 700 mg/day), there were no statistically significant rela-
tionship between calcium intake and the risk of stroke in 
women. Nevertheless, a further secondary analysis includ-
ing only female participants having ever used HRT at base-
line (n = 3261) revealed that in this population, compared 
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3594 3594 3593 3594 3593
Age, mean (SD) 58.43 (9.18) 58.85 (9.11) 59.21 (9.32) 59.32 (9.34) 58.41 (9.09) < 0.001
Females, N (%) 2185 (60.8) 2118 (58.932) 2039 (56.749) 1973 (54.897) 1729 (48.121) < 0.001
Body mass index, 
mean (SD)




Total energy intake 
(kJ), mean (SD)
6533.92 (1612.44) 7674.60 (1666.97) 8534.76 (1803.94) 9368.13 (2056.31) 11,144.41 (2535.38) < 0.001













Vegetable intake (g), 
mean (SD)
226.53 (110.31) 251.74 (114.23) 267.21 (117.50) 282.62 (122.74) 325.34 (167.53) < 0.001
Alcohol intake (g), 
median (IQR)
4.68 (0.76–11.85) 4.68 (0.92–10.88) 4.59 (0.76–10.64) 3.62 (0.76–10.18) 4.03 (0.76–10.52) < 0.001
Calcium intake (mg), 
mean (SD)
633.94 (110.22) 853.98 (45.11) 999.91 (42.61) 1159.35 (51.66) 1447.12 (185.02) < 0.001
Vitamin D (µg), 
mean (SD)
2.35 (1.64–3.27) 2.81 (2.05–3.93) 3.11 (2.27–4.43) 3.40 (2.46–4.83) 4.12 (2.89–5.94) < 0.001
Calcium supple-
ments, N (%)
1389 (38.65) 1484 (41.291) 1463 (40.718) 1536 (42.738) 1569 (43.668) < 0.001
Vitamin supple-
ments, N (%)
1470 (40.9) 1537 (42.766) 1537 (42.778) 1578 (43.907) 1596 (44.42) 0.029
Hormone replace-
ment therapy, used 
now or in the past, 
N (%)




134.81 (18.48) 134.80 (18.44) 135.29 (17.82) 134.87 (18.32) 134.73 (17.71) 0.700
Total cholesterol 
levels, mean (SD)
6.25 (1.19) 6.19 (1.14) 6.16 (1.14) 6.11 (1.12) 6.02 (1.10) < 0.001
Smoking status, N 
(%)
< 0.001
Current smoker 477 (13.27) 411 (11.436) 361 (10.047) 351 (9.766) 338 (9.407)
Former smoker 1493 (41.54) 1513 (42.098) 1477 (41.108) 1435 (39.928) 1463 (40.718)
Never smoker 1624 (45.19) 1670 (46.466) 1755 (48.845) 1808 (50.306) 1792 (49.875)
Social status, N (%) 0.406
Professional 226 (6.29) 239 (6.65) 265 (7.375) 263 (7.32) 268 (7.46)
Manager 1343 (37.37) 1291 (35.921) 1312 (36.515) 1334 (37.117) 1302 (36.237)
Skilled non-manual 590 (16.42) 610 (16.973) 609 (16.95) 640 (17.807) 571 (15.892)
Skilled manual 820 (22.82) 828 (23.038) 818 (22.766) 820 (22.816) 838 (23.323)
Semi-skilled 494 (13.75) 497 (13.829) 466 (12.97) 423 (11.77) 492 (13.693)
Non-skilled 121 (3.37) 129 (3.589) 123 (3.423) 114 (3.172) 122 (3.395)
Education level, N 
(%)
0.019
No qualification 2780 (77.35) 2766 (76.962) 2771 (77.122) 2729 (75.932) 2698 (75.09)
O-level 374 (10.41) 397 (11.046) 374 (10.409) 378 (10.518) 363 (10.103)
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to the lowest quintile of calcium intake (≤ 770 mg/day), the 
second (771–926 mg/day), third (927–1073 mg/day) and 
fourth (1074–1254 mg/day) quintiles were associated with 
a 27–30% lower risk of all-cause mortality (Supplementary 
Table 7). Furthermore, compared to the lowest quintile of 
calcium intake (≤ 770 mg/day), the highest quintile of cal-
cium intake (≥ 1255 mg/day) was associated with a 75% 
decrease in the risk of incident aortic stenosis in this popula-
tion, HR(95%CI): 0.25(0.06–0.95).
A secondary analysis restricting the analysed partici-
pant population to those without prevalent hypertension 
or diabetes mellitus at baseline (n = 15,396) revealed that 
the associations between calcium intake and all-cause and 
cardiovascular mortality were not preserved (Supplemen-
tary Table 8). Nevertheless, compared to the first quintile of 
calcium intake (< 770 mg/day), the second (771–926 mg/
day), third (927–1073 mg/day) and fourth (1074–1254 mg/
day) quintiles were associated with a decreased rate of inci-
dent stroke, respective HR (95%CI): 0.78 (0.66–0.94), 0.81 
(0.67–0.97) and 0.75 (0.62–0.91). There was no association 
between the fifth quintile (≥ 1255 mg/day) of calcium intake 
and incident stroke in this population either.
Finally, RCS analyses modelling the non-linear relation-
ship between calcium intake as a continuous variable and 
the pre-specified outcomes revealed similar results to the 
main analysis (Supplementary Figure 2). Compared to the 
mean daily calcium intake (1018.83 mg/day), lower cal-
cium intake values were associated with significantly lower 
risk of all-cause mortality while there were no associations 
between higher-than-mean values of calcium intake and 
all-cause mortality. There were no associations between 
calcium intake as a continuous variable and cardiovascular 
Bold values indicate the statistically significant results (P < 0.05)
SD Standard deviation, IQR Inter-quartile range, ACE Angiotensin converting enzyme












Inactive 1125 (31.3) 1044 (29.048) 1037 (28.862) 1023 (28.464) 828 (23.045)
Moderately Inactive 1062 (29.55) 1102 (30.662) 1062 (29.557) 1015 (28.242) 1018 (28.333)
Moderately active 829 (23.07) 829 (23.066) 792 (22.043) 887 (24.68) 880 (24.492)
Active 578 (16.08) 619 (17.223) 702 (19.538) 669 (18.614) 867 (24.13)
Prevalent comor-
bidities at baseline, 
N (%)
Diabetes 58 (1.61) 73 (2.031) 63 (1.753) 72 (2.003) 61 (1.698) 0.589
Hypertension 459 (12.77) 479 (13.328) 486 (13.526) 481 (13.383) 439 (12.218) 0.441
Medications at base-
line, N (%)
Aspirin 171 (4.76) 180 (5.008) 199 (5.539) 193 (5.37) 178 (4.954) 0.555
Beta blockers 203 (5.65) 184 (5.12) 195 (5.427) 210 (5.843) 174 (4.843) 0.336




1817 (50.56) 1875 (52.17) 1926 (53.604) 1896 (52.755) 1873 (52.129) 0.127
Incident acute myo-
cardial infarction
196 (5.45) 215 (5.982) 196 (5.455) 233 (6.48) 193 (5.372) 0.197
Incident cerebrovas-
cular disease
356 (9.91) 323 (8.987) 332 (9.24) 332 (9.238) 366 (10.186) 0.365
Incident cardiac 
failure
316 (8.79) 332 (9.238) 307 (8.544) 353 (9.82) 311 (8.66) 0.306
Incident aortic 
stenosis
80 (2.23) 72 (2.003) 88 (2.449) 80 (2.226) 82 (2.282) 0.795
Incident peripheral 
vascular disease
269 (7.48) 260 (7.234) 268 (7.46) 258 (7.179) 274 (7.626) 0.948
Incident all-cause 
mortality




321 (8.93) 274 (7.62) 328 (9.129) 314 (8.737) 303 (8.433) 0.174
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mortality, incident all-cardiovascular disease, aortic ste-
nosis, cardiac failure, myocardial infarction or peripheral 
arterial disease. Compared to the mean daily calcium intake 
(1018.83 mg/day), both very low (≤ 638 mg/day) and very 
high (≥ 1514 mg/day) daily calcium intake values were asso-
ciated with significantly increased risk of incident stroke.
Table 2  Results of Cox regressions assessing the relationship between quintiles of calcium intake and incident mortality and cardiovascular 
events in 17,968 men and women of the EPIC-Norfolk study
Bold values indicate the statistically significant results (P < 0.05)
Adjusted for age, sex, body mass index, systolic blood pressure, low-density lipoprotein, high-density lipoprotein and total cholesterol levels, 
social class, education level, physical activity, alcohol intake, smoking status, pre-existing comorbidities (hypertension, stroke, myocardial 
infarction, diabetes), medication and supplement use (aspirin, statins, ACE inhibitors, beta-blockers, angiotensin receptor blockers, vitamin 
supplement use), dietary intake (total energy intake, fruit and vegetable, vitamin D and calcium intake) and current/former usage of hormone 
replacement therapy (HRT)
HR - hazard ratio; 95% CI - 95% confidence interval








Calcium intake ≥ 1255 mg/
day
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
All-cause mortality




0.159 1.00 (0.91–1.09) 0.942 0.99 (0.91–1.08) 0.825




0.291 0.85 (0.77–0.93) 0.001 0.93 (0.83–1.04) 0.207
Cardiovascular mortality




0.680 0.97 (0.83–1.14) 0.741 0.94 (0.81–1.10) 0.463




0.203 0.80 (0.67–0.95) 0.012 0.87 (0.71–1.07) 0.187
Incident all cardiovascular disease




0.031 1.04 (0.98–1.11) 0.203 1.03 (0.96–1.10) 0.399




0.817 0.94 (0.88–1.01) 0.102 1.02 (0.94–1.11) 0.601
Incident aortic stenosis




0.476 1.00 (0.73–1.36) 0.978 1.02 (0.75–1.39) 0.878




0.907 0.87 (0.62–1.24) 0.445 0.96 (0.64–1.43) 0.832
Incident cardiac failure




0.813 1.11 (0.96–1.30) 0.163 0.98 (0.84–1.15) 0.805




0.223 0.98 (0.83–1.17) 0.854 1.00 (0.82–1.22) 0.981
Incident myocardial infarction




0.936 1.19 (0.98–1.44) 0.074 0.98 (0.81–1.20) 0.872




0.491 1.06 (0.85–1.31) 0.610 0.92 (0.71–1.18) 0.492
Incident peripheral arterial disease




0.931 0.95 (0.80–1.13) 0.566 1.02 (0.86–1.20) 0.841




0.802 0.93 (0.77–1.12) 0.441 1.08 (0.87–1.34) 0.506
Incident stroke




0.405 0.93 (0.80–1.08) 0.321 1.03 (0.89–1.19) 0.721




0.021 0.78 (0.66–0.92) 0.003 0.95 (0.78–1.15) 0.584
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Meta‑analysis of prospective cohort studies 
including EPIC‑Norfolk study
Supplementary Table 3 shows the details of the studies 
included in the meta-analysis. The results of the meta-
analyses are displayed in Figs. 2, 3 and 4. Figure 2 details 
the pooled results of studies evaluating the association 
between calcium intake and all-cause mortality, strati-
fied by average calcium intake (low versus high). We 
included the risk ratios between the highest and lowest 
category of calcium intake, as defined by each individual 
study (Supplementary Table 3). Amongst studies with a 
low average calcium intake (< 700 mg/day), we identi-
fied an association between higher calcium intake and a 
decreased all-cause mortality risk, RR (95%CI) = 0.89 
(0.80–0.99). This association was also identified amongst 
studies with a high average calcium intake (≥ 700 mg/day), 
RR (95%CI) = 0.93 (0.89–0.98). Supplementary Figure 3 
details the pooled results of studies evaluating the associa-
tion between calcium dietary intake and all-cause mortal-
ity, stratified by average calcium intake and sex. Amongst 
men, higher calcium intake was associated with decreased 
all-cause mortality in studies with low average calcium 
intake [0.82 (0.70–0.98)], but not in those with high 
average calcium intake [0.94 (0.82–1.09)]. Conversely, 
amongst women, higher dietary calcium intake was asso-
ciated with decreased all-cause mortality in studies with 
high average calcium intake [0.95 (0.91-0.99)], but not in 
those with low average calcium intake [1.02 (0.96-1.07)].
Figure 3 details the pooled results of studies evaluating 
the association between calcium intake and cardiovascular 
mortality, stratified by average calcium intake (low versus 
high). We included the risk ratios between the highest and 
lowest category of calcium intake, as defined by each indi-
vidual study (Supplementary Table 3). There was no asso-
ciation between calcium intake and cardiovascular mortality 
amongst either studies with low average calcium intake [0.99 
(0.93–1.06)] or those with high average calcium intake [0.98 
(0.94–1.02)]. Supplementary Figure 4 details the pooled 
results of studies evaluating the association between calcium 
dietary intake and all-cause mortality, stratified by average 
calcium intake and sex. Similarly, there were no associations 
between dietary calcium intake and cardiovascular mortality 
amongst either men or women from studies with either low 
or high average dietary calcium intake.
Figure 4 details the pooled results of the studies evalu-
ating the association between calcium supplementation 
(use versus non-use) and mortality (cardiovascular and 
all-cause). Whilst calcium supplementation was associ-
ated with decreased all-cause mortality amongst women 
[0.89 (0.87–0.91)], there was no association between cal-
cium supplementation and all-cause mortality amongst men 
[1.01 (0.98–1.04)]. Similarly, calcium supplementation was 
associated with decreased cardiovascular mortality amongst 
women [0.85 (0.77–0.94)], while there was no association 
between calcium supplementation and cardiovascular mor-
tality amongst men [0.96 (0.87–1.04)].
Discussion
The results of our prospective cohort study with > 20 years 
of follow-up suggest that, compared to a dietary calcium 
intake below 770 mg/day, intakes between 771–926 mg/
day and 1074–1254 mg/day may be protective against both 
Table 3  Results of Cox regression assessing the relationship between 
calcium incident use and incident mortality and cardiovascular events 
in 17,968 men and women of the EPIC-Norfolk study
Adjusted for age, sex, body mass index, systolic blood pressure, low-
density lipoprotein, high-density lipoprotein and total cholesterol 
levels, social class, education level, physical activity, alcohol intake, 
smoking status, pre-existing comorbidities (hypertension, stroke, 
myocardial infarction, diabetes), medication and supplement use 
(aspirin, statins, ACE inhibitors, beta-blockers, angiotensin receptor 
blockers, vitamin supplement use), dietary intake (total energy intake, 
fruit and vegetable, vitamin D and calcium intake) and current/former 
usage of hormone replacement therapy (HRT)
HR - hazard ratio; 95% CI - 95% confidence interval





Unadjusted 1.00 (ref) 1.03 (0.97–1.08) 0.380
Fully adjusted 1.00 (ref) 1.01 (0.93–1.10) 0.825
All-cause mortality
Unadjusted 1.00 (ref) 1.01 (0.92–1.12) 0.806
Fully adjusted 1.00 (ref) 0.88 (0.76–1.03) 0.103
Incident all cardiovascular disease
Unadjusted 1.00 (ref) 1.01 (0.97–1.06) 0.492
Fully adjusted 1.00 (ref) 1.00 (0.94–1.06) 0.919
Incident aortic stenosis
Unadjusted 1.00 (ref) 1.04 (0.86–1.27) 0.681
Fully adjusted 1.00 (ref) 1.01 (0.75–1.35) 0.969
Incident cardiac failure
Unadjusted 1.00 (ref) 0.97 (0.88–1.07) 0.563
Fully adjusted 1.00 (ref) 0.92 (0.80–1.06) 0.255
Incident myocardial infarction
Unadjusted 1.00 (ref) 0.87 (0.77–0.99) 0.034
Fully adjusted 1.00 (ref) 0.95 (0.79–1.15) 0.606
Incident peripheral arterial disease
Unadjusted 1.00 (ref) 0.90 (0.81–1.01) 0.065
Fully adjusted 1.00 (ref) 1.01 (0.86–1.19) 0.927
Incident stroke
Unadjusted 1.00 (ref) 0.98 (0.89–1.08) 0.702
Fully adjusted 1.00 (ref) 0.96 (0.83–1.10) 0.559
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all-cause and cardiovascular mortality. We have also shown 
that, when compared to intakes below 770 mg/day, higher 
dietary calcium intakes below 1255 mg/day may be pro-
tective against incident stroke. Furthermore, we found no 
association between calcium intake and incident all-cardio-
vascular disease, as well as incident aortic stenosis, cardiac 
failure, myocardial infarction or peripheral vascular disease. 
Thus, calcium intake exhibited a ‘U’-shaped relationship 
with the risk of incident stroke with very low and very 
high intake values being associated with a higher risk. Our 
analyses also revealed several sex differences, in which the 
associations between calcium intake and incident adverse 
outcomes were only exhibited amongst men but not women. 
Another important subgroup to consider are women using 
HRT, in whom we found a ‘U’-shaped relationship between 
calcium intake and all-cause mortality, with very low and 
very high intake values being associated with a higher risk. 
Finally, we found no association between calcium supple-
ment use and cardiovascular or all-cause mortality or inci-
dent cardiovascular disease. The results of our meta-analysis 
Fig. 2  Meta-analysis (forest plot) of the association between dietary 
calcium intake (highest compared to the lowest level, mg/day) and 
risk of all-cause mortality stratified by low/high average (median) cal-
cium intake among prospective cohort studies and the EPIC-Norfolk 
study. The diamond represents the summary risk ratio (pooled RR) 
estimate and its width shows corresponding 95% CI with random 
effects estimate. The size of the square and its central point reflect the 
study specific statistical weight (inverse of variance) and point esti-
mate of the risk ratio respectively. The horizontal line reflects corre-
sponding 95% CI. I2 test and Cochran’s Q statistic were used to assess 
statistical heterogeneity (P < 0.10) across studies. Odds ratios, hazard 
ratios and risk ratios from the primary studies were pooled together 
and the results expressed as risk ratios, as the outcomes of interest are 
rare events
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showed that higher dietary calcium intake was associated 
with lower all-cause mortality, but not cardiovascular mor-
tality. Sex-stratified analyses revealed that amongst men, the 
association between higher dietary calcium intake and all-
cause mortality was mainly driven by studies with low aver-
age calcium intake, while amongst women this association 
was driven by studies with a high average calcium intake. 
Finally, our meta-analysis also revealed that calcium sup-
plementation was associated with decreased all-cause and 
cardiovascular mortality amongst women, but not men.
Previous systematic reviews have yielded highly heterog-
enous results, with some suggesting that an increased intake 
of calcium may be associated with an increased risk of car-
diovascular disease [12, 13] and mortality, whilst others 
Fig. 3  Meta-analysis (forest plot) of the association between dietary 
calcium intake (highest compared to the lowest level, mg/day) and 
risk of cardiovascular (CVD) mortality stratified by low/high aver-
age (median) calcium intake among prospective cohort studies and 
the EPIC-Norfolk study. The diamond represents the summary risk 
ratio (pooled RR) estimate and its width shows corresponding 95% 
CI with random effects estimate. The size of the square and its central 
point reflect the study specific statistical weight (inverse of variance) 
and point estimate of the risk ratio respectively. The horizontal line 
reflects corresponding 95% CI. I2 test and Cochran’s Q statistic were 
used to assess statistical heterogeneity (P < 0.10) across studies. Odds 
ratios, hazard ratios and risk ratios from the primary studies were 
pooled together and the results expressed as risk ratios, as the out-
comes of interest are rare events
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found no association [15, 16]. A further review, despite hav-
ing included nine studies that found no association between 
increased dietary calcium intake and cardiovascular mor-
tality, has found a U-shaped relationship between calcium 
intake and cardiovascular mortality [14]. Thus, the highest 
and the lowest consumers of calcium were at the greatest 
risk. Furthermore, a threshold effect was reported for the 
association between calcium intake and all-cause mortality: 
intakes lower than 900 mg/day were associated with a higher 
mortality risk, whilst increases in intake beyond 900 mg/
day were not associated with any further risk decreases. The 
latter finding may potentially account for the lack of over-
all effect in our analysis, given that in our database cohort 
900 mg/day represents approximately the 36th centile. Simi-
larly, a previous meta-analysis has found that whilst calcium 
intakes ranging between 200 and 1500 mg/day were not 
associated with incident cardiovascular disease, but found 
an association between calcium supplementation and inci-
dent myocardial infarction [16]. One of the most striking 
results of our database analysis was that stroke incidence 
may be reduced in association with an increased dietary cal-
cium intake, but only up to 1255 mg/day. This may be poten-
tially explained through the intermediate antihypertensive 
properties of calcium [7], which is a major risk factor for 
stroke. Nevertheless, the fact that intakes above 1255 mg/
day cease to be protective against incident stroke may be 
attributed to the association between serum calcium levels 
and carotid artery plaque thickness [8].
Our study benefits from several strengths. Our database 
study was based on a large prospective cohort with a very 
long follow-up (> 20 years). Furthermore, our study cohort 
included both males and females allowing for a more com-
prehensive analysis than those studies focussing solely on 
men [25] or women [2, 5, 30]. We were also able to adjust 
for a wide range of potential confounders including socio-
demographic, lifestyle, co-morbidity, medication and sup-
plement use data.
Nevertheless, a few limitations of our study should be 
considered. Firstly, as a prospective cohort study, calcium 
exposure was not randomly assigned, raising the possibil-
ity of residual confounding. Furthermore, given the lack of 
time-updated data on participant characteristics, we only 
adjusted our time-to-event analyses with a long follow-up 
time for participant characteristics at baseline. Addition-
ally, dietary intakes were calculated from food frequency 
questionnaires (FFQ), which may be prone to recall bias. 
Fig. 4  Meta-analysis (forest plot) of the association between calcium 
supplements (use versus non-use) and risk of all-cause and cardio-
vascular mortality stratified by sex among prospective cohort studies 
and EPIC-Norfolk study. The diamond represents the summary risk 
ratio (pooled RR) estimate and its width shows corresponding 95% 
CI with random effects estimate. The I2 test and Cochran’s Q statistic 
were used to assess statistical heterogeneity (P < 0.10) across studies. 
Odds ratios, hazard ratios and risk ratios from the primary studies 
were pooled together and the results expressed as risk ratios, as the 
outcomes of interest are rare events
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However, the FFQ used in the EPIC-Norfolk study has been 
validated and required participants to consider their average 
dietary intake over a long period of time, covering a longer 
duration than methods such as the seven-day dietary diary 
or 24-h dietary recall [45]. Our study also analysed calcium 
intake regardless of dietary source and we were thus unable 
to draw conclusions dependent of the dietary source of cal-
cium. Finally, our study data did not allow for consideration 
of the water intake of individual participants. Nevertheless, 
a previous study found no association between high water 
hardness and incident coronary heart disease in a British 
cohort [46].
In conclusion, our results demonstrate that moderate 
dietary calcium intake may be beneficial against cardio-
vascular and all-cause mortality as well as incident stroke 
in the general adult population, compared to low and high 
intakes. Our results suggest that these associations are more 
likely to be observed amongst men as well as women hav-
ing received HRT. Calcium supplementation use was not 
associated with increased mortality or cardiovascular risk 
in our population. Nevertheless, calcium supplementation 
may be associated with decreased all-cause and cardiovas-
cular mortality amongst women based on our meta-analysis 
results. The clinical implications of our study in the UK 
setting may be that those with risk factors for stroke should 
be encouraged to meet the UK dietary calcium recommen-
dations of ≥ 700 mg/day, but not exceed a higher limit of 
1255 mg of calcium per day. Additionally, a moderate intake 
of dietary calcium (771–926 mg/day) [47] may be a protec-
tive factor against mortality. Calcium supplementation may 
also be actively encouraged amongst women. More research 
is needed to establish a clear association between calcium 
intake and incident stroke and other cardiovascular disease, 
with particular emphasis on determining whether an upper 
threshold of dietary calcium intake for this relationship does 
indeed exist.
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